Details:

Alternative Title:
Emerg Infect Dis
Personal Author:
Geisbert, Thomas W. ; Pushko, Peter ; Anderson, Kevin ; Smith, Jonathan ; Davis, Kelly J. ; ... More +
Geisbert, Thomas W. ; Pushko, Peter ; Anderson, Kevin ; Smith, Jonathan ; Davis, Kelly J. ; Jahrling, Peter B. Less -
Description:
Ebola virus (EBOV) causes acute hemorrhagic fever that is fatal in up to 90% of cases in both humans and nonhuman primates. No vaccines or treatments are available for human use. We evaluated the effects in nonhuman primates of vaccine strategies that had protected mice or guinea pigs from lethal EBOV infection. The following immunogens were used: RNA replicon particles derived from an attenuated strain of Venezuelan equine encephalitis virus (VEEV) expressing EBOV glycoprotein and nucleoprotein; recombinant Vaccinia virus expressing EBOV glycoprotein; liposomes containing lipid A and inactivated EBOV; and a concentrated, inactivated whole-virion preparation. None of these strategies successfully protected nonhuman primates from robust challenge with EBOV. The disease observed in primates differed from that in rodents, suggesting that rodent models of EBOV may not predict the efficacy of candidate vaccines in primates and that protection of primates may require different mechanisms.
Subjects:
[+]
Animals Antibodies, Viral Ebolavirus Encephalitis Virus, Venezuelan Equine Genetic Vectors Glycoproteins Hemorrhagic Fever, Ebola Immunization Macaca Macaca Fascicularis Macaca Mulatta Nucleoproteins Replicon Vaccines, Attenuated Vaccines, Synthetic Viral Proteins Viral Vaccines
Source:
Emerg Infect Dis. 8(5):503-507.
Document Type:
Journal Article
Collection(s):
Emerging Infectious Diseases
Main Document Checksum:
[+]
urn:sha256:dff9208a341d9284c7e13dff1f108187bbe9cd6c0687447eb1b1d6c3a926f245
Download URL:
https://stacks.cdc.gov/view/cdc/13815/cdc_13815_DS1.pdf
File Type:

Supporting Files

• 	01-0284-F.gif	gif
  	01-0284-F.jpg	jpeg
  	01-0284.nxml	txt
  	license.txt	txt

More +